Scholars Central

LetterPublished 27 Jun 2016

Rethinking Demethylating Agents in Epigenetic Cancer Therapy

Authors: Fides D Lay, Gangning Liang

1Department of Molecular Cell and Developmental Biology, University of California, Los Angeles, CA, USA; 2Department of Urology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

DNA methylation inhibitors 5-Azacytidine and 5-Aza-2’-deoxycytidine have been increasingly used in the clinic to treat myeloid disorders and cancer since their FDA approval over a decade ago. Increasing the efficiency and efficacy of these drugs require better understanding on their mechanism of action. Recent studies show that DNA methylation inhibitors have widespread anti-tumor functions and act by modulating oncogenes and tumor suppressor genes expression as well as stimulating the immune system. These findings demonstrate the significant progress that has been made in the field of epigenetic therapy to improve patients’ outcome.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Molecular Pharmaceutics & Organic Process Research
  • SubjectPharmaceutical Sciences
  • SubjectChemistry
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “Fides D Lay”
  • BylineArticles whose byline prints “Gangning Liang”